Contact Us
Drug Search Results
More Filters [+]

CRX-100

Alternative Names: crx-100, crx 100, crx100
Latest Update: 2024-01-31
Latest Update Note: Clinical Trial Update

Product Description

CRX-100 is being developed by BioEclipse Therapeutis for the treatment of patients with advanced solid tumors. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04282044?term=CRX-100&draw=2&rank=1)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: BioEclipse Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CRX-100

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Colorectal Cancer|Gastrointestinal Cancer|Hepatocellular Carcinoma|Melanoma|Non-Small-Cell Lung Cancer|Osteosarcoma|Ovarian Cancer|Triple Negative Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CRX100-001

P1

Recruiting

Non-Small-Cell Lung Cancer|Colorectal Cancer|Melanoma|Ovarian Cancer|Osteosarcoma|Hepatocellular Carcinoma|Triple Negative Breast Cancer|Gastrointestinal Cancer

2025-08-01

27%

Recent News Events

Date

Type

Title

04/26/2022

News Article

 BioEclipse Therapeutics™ Awarded Almost $8 Million Grant by California Institute for Regenerative Medicine (CIRM) to Fund Ongoing Phase 1 CRX100 Cancer Immunotherapy Clinical Trial

01/26/2022

News Article

 BioEclipse Therapeutics Appoints New Board Member and Names Interim CFO

09/10/2021

News Article

 BioEclipse Therapeutics™ to Present at Virtual H.C. Wainwright 23rd Annual Global Healthcare Conference

03/29/2021

News Article

 BioEclipse Therapeutics™ to Present at the Spring 2021 Virtual Oncology Investor Conference

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions